All In Biotech

Drug Trial Radar · NCT02441062

Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors

Last checked: Nov 20, 2026Latest source record: Dec 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

122

Actual

Start

Sep 2015

Primary completion

Jan 20, 2020

Study completion Jan 20, 2020

Sponsor

Lead sponsor
Sue O'DorisioAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Iowa
First posted
May 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Participants in this study have been diagnosed with a tumor such as a carcinoid, neuroendocrine tumor, neuroblastoma, Ewing's sarcoma, or brain tumor that has cells which carry somatostatin receptors. The purpose of this research study is to see if the tumor can be identified using a special procedure called a positron emission tomography (PET) scan and how the results of this imaging procedure will change the management of the tumor.

Conditions

  • Neuroendocrine Tumors
  • Carcinoid Tumors
  • Neuroblastoma
  • Medulloblastoma

Interventions

  • 68Ga-DOTATOC PET/CTDrug

    Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT ScanTime frame: 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.